Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting

• Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical Research
  
  
• Phase 1 population PK data abstract concludes the large body of pre-existing clinical data related to vonoprazan in Asian populations can be reliably applied to non-Asian populations
  
  
• Real-world physician and patient-based Study of Acid-Related Disorders (SOARD) provides perceptions of disease burden and highlights unmet needs in the treatment of H. pylori and erosive esophagitis
  

FLORHAM PARK, N.J., Oct. 24, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today data from the PHALCON-HP Phase 3 study, the largest U.S. registrational trial ever conducted for H. pylori, will be presented during an oral session at the ACG 2021 Annual Scientific Meeting organized by the American College of Gastroenterology, in Las Vegas, Nevada, Oct. 22-27. In advance of the oral presentation, the abstract was selected as the recipient of the ACG Governors Award for Excellence in Clinical Research.

PHALCON-HP showed that both vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) and vonoprazan in combination with amoxicillin (vonoprazan dual therapy) demonstrated superior eradication rates in all patients compared to a current standard of care therapy consisting of the proton pump inhibitor (PPI), lansoprazole, in combination with amoxicillin and clarithromycin.

“Eradication rates with PPI-based triple therapy for H. pylori infection has been declining over the last two decades, mainly due to increased resistance to antibiotics,” said Professor William D. Chey, M.D., AGAF, FACG, FACP, Professor of Medicine and Director of the GI Physiology Laboratory at Michigan Medicine. “This study demonstrated meaningfully enhanced eradication rates for these vonoprazan regimens versus a standard of care PPI-based triple therapy and highlighted the potential for a new antibiotic-sparing dual therapy treatment option.”